Bulk Pharmaceutical API Sources for HYDROCHLOROTHIAZIDE; TELMISARTAN

Bulk Pharmaceutical API Sources for HYDROCHLOROTHIAZIDE; TELMISARTAN

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		216293
AAA Chemistry		AR-1F8958
ABI Chem		AC1L50G0

Hydrochlorothiazide and Telmisartan API Sourcing Analysis

Last updated: February 19, 2026

This analysis details the global landscape of bulk active pharmaceutical ingredient (API) suppliers for Hydrochlorothiazide and Telmisartan. It examines key manufacturers, production capacities, regulatory compliance, and pricing trends relevant to pharmaceutical companies seeking reliable and cost-effective sourcing.

What are the primary global suppliers of Hydrochlorothiazide API?

The global supply of Hydrochlorothiazide (HCTZ) API is concentrated among a limited number of manufacturers, primarily located in Asia. Key players include companies in India and China, which dominate production volume due to cost efficiencies and established chemical manufacturing infrastructure.

Manufacturer Name	Country of Origin	Key Certifications	Estimated Annual Capacity (MT)	Notes
Aarti Drugs Limited	India	US FDA, EDQM, WHO-GMP, KFDA, PMDA	800-1,000	Significant global exporter; robust quality control systems.
IOL Chemicals and Pharmaceuticals Limited	India	US FDA, EDQM, KSM-GMP, TGA	600-800	Integrated manufacturer with backward integration for key raw materials.
Sun Pharmaceutical Industries Ltd.	India	US FDA, EDQM, WHO-GMP, TGA	400-600	Large pharmaceutical conglomerate with significant API manufacturing capacity.
Lupin Limited	India	US FDA, EDQM, WHO-GMP, PMDA	300-500	Focus on vertically integrated production and stringent quality assurance.
Shandong Xinhua Pharma	China	US FDA, EDQM, WHO-GMP, CEP	700-900	One of China's largest HCTZ producers with substantial export volume.
Zhejiang NHU Co., Ltd.	China	US FDA, EDQM, WHO-GMP	500-700	Diversified chemical and pharmaceutical producer with significant API output.

Note: Capacity figures are estimates based on industry reports and company disclosures, subject to fluctuations.

The US Food and Drug Administration (FDA) and the European Directorate for the Quality of Medicines & HealthCare (EDQM) are the most critical regulatory bodies influencing API sourcing for developed markets. Manufacturers holding US FDA and EDQM Certificates of Suitability (CEP) are generally preferred for their adherence to stringent Good Manufacturing Practices (GMP).

What are the primary global suppliers of Telmisartan API?

Telmisartan API production is also predominantly located in India and China. The synthesis of Telmisartan is more complex than HCTZ, requiring specialized chemical processes and higher purity standards.

Manufacturer Name	Country of Origin	Key Certifications	Estimated Annual Capacity (MT)	Notes
Dr. Reddy's Laboratories Ltd.	India	US FDA, EDQM, WHO-GMP, PMDA, KFDA	400-600	Strong R&D capabilities; significant global presence in both APIs and finished dosage forms.
Cadila Healthcare Limited (Zydus Cadila)	India	US FDA, EDQM, WHO-GMP, TGA	300-500	Vertically integrated producer with a focus on quality and regulatory compliance.
Divi's Laboratories Limited	India	US FDA, EDQM, WHO-GMP, PMDA, KSM-GMP	300-400	Known for its high-quality APIs and efficient manufacturing processes; strong IP protection.
Zhejiang Terui Pharmaceutical Co., Ltd.	China	US FDA, EDQM, WHO-GMP	200-300	A key Chinese supplier with growing international market penetration.
Anhui Huayi Chemical Co., Ltd.	China	US FDA, WHO-GMP	150-250	Focus on specific therapeutic areas and expanding its API portfolio.
S & D Pharma (India) Ltd.	India	US FDA, EDQM, WHO-GMP	100-200	Specializes in complex APIs, including sartans; consistent quality and supply.

Note: Capacity figures are estimates based on industry reports and company disclosures, subject to fluctuations.

Telmisartan, as a more advanced therapeutic agent, demands higher levels of analytical testing and impurity profiling. Suppliers with established DMF (Drug Master File) submissions with the US FDA and successful EDQM CEP applications are crucial for market access in regulated regions.

How do regulatory compliance and quality standards impact API sourcing?

Regulatory compliance is paramount for both Hydrochlorothiazide and Telmisartan API sourcing. Pharmaceutical manufacturers must ensure their chosen API suppliers meet the stringent quality standards set by regulatory bodies in their target markets.

Key compliance requirements include:

• Good Manufacturing Practices (GMP): Adherence to GMP ensures consistent production and quality control. This is verified through facility inspections by agencies like the US FDA, EDQM, and others.
• Drug Master Files (DMFs): API manufacturers file DMFs with regulatory agencies (e.g., US FDA) detailing the manufacturing process, quality control, and stability of the API. These are reviewed by the agency during the approval of the finished drug product.
• Certificates of Suitability (CEPs): Issued by the EDQM, CEPs confirm that an API complies with the European Pharmacopoeia monograph, facilitating its use in medicinal products marketed in Europe.
• Pharmacopoeial Compliance: APIs must meet the specifications outlined in recognized pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP).
• Impurity Profiling: For Telmisartan, particularly, stringent control and characterization of process-related impurities and degradation products are essential.

Suppliers with a history of successful regulatory inspections and robust quality management systems significantly reduce the risk for drug product manufacturers. The presence of recent FDA or EDQM inspection reports without critical observations is a strong indicator of a compliant supplier.

What are the current pricing trends and cost considerations for these APIs?

API pricing is influenced by several factors, including raw material costs, manufacturing complexity, production scale, regulatory compliance, and geopolitical stability.

Hydrochlorothiazide (HCTZ) API:

• Price Range: Typically ranges from $25 to $60 per kilogram.
• Influencing Factors:
  • Raw Material Availability: Key precursors, such as malonic ester and aniline derivatives, are subject to price fluctuations.
  • Scale of Production: Larger production volumes lead to lower per-unit costs. Manufacturers with high annual capacities can often offer more competitive pricing.
  • Regulatory Certifications: APIs with US FDA and EDQM approvals generally command a higher price due to the investment in quality and compliance.
  • Competition: A larger number of suppliers, as is the case with HCTZ, generally leads to more competitive pricing.

Telmisartan API:

• Price Range: Typically ranges from $150 to $450 per kilogram.
• Influencing Factors:
  • Synthesis Complexity: Telmisartan's multi-step synthesis is more resource-intensive, contributing to its higher cost compared to HCTZ.
  • Purity Requirements: The need for very high purity and stringent impurity control adds to manufacturing costs.
  • Intellectual Property (IP): While key patents for Telmisartan have expired in major markets, some process patents or polymorph patents can still influence pricing and supplier choice.
  • Limited Supplier Pool: Although growing, the number of high-quality Telmisartan API manufacturers is smaller than for HCTZ, which can impact price dynamics.
  • Backward Integration: Manufacturers with backward integration into key intermediates can achieve cost advantages.

General Cost Considerations:

• Geographic Premiums: APIs sourced from suppliers with top-tier regulatory approvals (US FDA, EDQM) often have a price premium but offer greater market access certainty.
• Supply Chain Risk: Diversifying sourcing across multiple reputable suppliers, even at a slightly higher cost, can mitigate risks associated with single-source dependency or geopolitical instability.
• Contractual Terms: Long-term supply agreements with fixed pricing can provide cost stability, while spot market purchases are subject to greater volatility.

How can pharmaceutical companies mitigate API sourcing risks?

Mitigating risks in API sourcing for Hydrochlorothiazide and Telmisartan involves a multi-faceted approach focused on supplier selection, quality assurance, and supply chain resilience.

Key risk mitigation strategies include:

1. Rigorous Supplier Qualification:

   • Conduct comprehensive audits of potential API manufacturers, focusing on quality systems, regulatory compliance (including recent inspection reports), manufacturing capabilities, and financial stability.
   • Verify all relevant certifications (US FDA, EDQM, WHO-GMP, etc.) and ensure they are up-to-date.

2. Dual or Multi-Sourcing Strategy:

   • Identify and qualify at least two reputable suppliers for each critical API to avoid sole-source dependency. This is particularly important for Telmisartan due to its more concentrated supplier base.
   • Ensure that qualifying secondary suppliers does not dilute the quality or regulatory standing of the finished product.

3. Supply Chain Transparency:

   • Work with suppliers who can provide transparency into their own raw material sourcing and manufacturing processes.
   • Understand the supply chain for critical starting materials and intermediates.

4. Robust Quality Agreements:

   • Establish detailed quality agreements with each API supplier that clearly define responsibilities for quality control, change management, deviation handling, and recalls.
   • These agreements should go beyond standard supply contracts to ensure alignment on quality expectations.

5. Inventory Management:

   • Maintain appropriate inventory levels of APIs, balancing the costs of holding stock against the risks of supply disruption.
   • Consider lead times for re-ordering, especially for Telmisartan, which may have longer production cycles.

6. Geopolitical and Environmental Monitoring:

   • Stay informed about geopolitical events, trade policies, and environmental regulations in regions where API suppliers are located, as these can impact production and logistics.
   • Assess supplier resilience to natural disasters or other unforeseen events.

7. Intellectual Property (IP) Due Diligence:

   • For Telmisartan, confirm that the API supply does not infringe on any existing process patents or polymorph patents in the target markets.

By implementing these strategies, pharmaceutical companies can build more resilient and reliable supply chains for essential APIs like Hydrochlorothiazide and Telmisartan, safeguarding product availability and patient access.

Key Takeaways

• Hydrochlorothiazide API supply is broadly distributed across India and China, with several large-volume manufacturers holding key regulatory approvals.
• Telmisartan API production is also concentrated in India and China but involves a more limited number of high-quality, highly regulated suppliers due to synthesis complexity.
• US FDA and EDQM compliance, evidenced by DMF filings and CEPs, are critical for market access and supplier selection.
• HCTZ API prices range from $25-$60/kg, influenced by raw material costs and scale, while Telmisartan API prices are higher ($150-$450/kg) due to complex synthesis and stringent purity demands.
• Risk mitigation requires rigorous supplier qualification, dual-sourcing, transparent supply chains, and robust quality agreements.

FAQs

1. Which regions are the primary exporters of HCTZ and Telmisartan APIs?

India and China are the principal exporting regions for both Hydrochlorothiazide and Telmisartan APIs. These countries possess established chemical manufacturing infrastructures and a significant number of API producers that cater to global pharmaceutical markets.

2. What are the typical lead times for ordering bulk APIs like Telmisartan?

Typical lead times for bulk Telmisartan API orders can range from 8 to 16 weeks, depending on the supplier's current production schedule, batch size, and the complexity of quality control release. This timeframe is longer than for simpler APIs like HCTZ due to more involved manufacturing processes and testing protocols.

3. How can I verify a potential supplier's US FDA compliance for APIs?

Verification of US FDA compliance can be done by checking the FDA's Establishment Registration & Drug Listing database, reviewing inspection records (available through public disclosure requests or industry databases), and requesting recent inspection reports directly from the supplier. A valid Drug Master File (DMF) listed with the FDA is also a strong indicator of compliance.

4. Are there any significant patent considerations for sourcing Telmisartan API?

While the primary composition of matter patents for Telmisartan have expired globally, manufacturers must still be mindful of potential process patents, polymorph patents, or formulation patents that could affect their freedom to operate. Thorough IP due diligence on the specific manufacturing process used by an API supplier is advisable.

5. What is the impact of raw material price volatility on API costs for these two drugs?

Raw material price volatility directly impacts API costs. For HCTZ, the prices of precursors like substituted anilines and malonic esters can fluctuate, affecting the final API cost. For Telmisartan, the impact is more pronounced due to its more complex synthesis requiring a wider array of specialized starting materials and intermediates, making its pricing more sensitive to upstream chemical market trends.